Video
Dr. Spratt discusses ongoing research with Decipher genomic testing
Author(s):
“I think that it's very clear that this test is independently prognostic,” says Daniel E. Spratt, MD.
In this video, Daniel E. Spratt, MD, discusses the takeaways of the study, “Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Spratt is a Vincent K. Smith professor and chair at Case Western Reserve University School of Medicine and chair of radiation oncology at University Hospitals Cleveland Medical Center in Cleveland, Ohio.
Related Videos
Related Content
